NovoCure (NSDQ:NVCR) said today that it was granted Innovative Medical Device Designation in China for its Optune tumor treating system.
The Optune system uses electric fields that are tuned in to specific frequencies to disrupt cancer cell division, according to the company. The technology inhibits tumor growth and causes cancer cells to die. Zai Lab has exclusive licensing rights to NovoCure’s Tumor Treat Fields and Optune in China.
Get the full story on our sister site, Drug Delivery Business.